We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current MCRB market cap is 157.8M. The company's latest EPS is USD -0.7531 and P/E is -1.37.
Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 975k | -522k | 126.47M | 310k | 64k |
Operating Income | -68.31M | -70.57M | 45.92M | -47.41M | -44.72M |
Net Income | -68.8M | -71.17M | 46.55M | -47.85M | -41.25M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 34.51M | 33.22M | 146.66M | 7.13M | 126.33M |
Operating Income | -71.88M | -88.13M | -64.49M | -246.49M | -107.98M |
Net Income | -70.28M | -89.13M | -65.58M | -250.16M | -113.72M |
Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 348.78M | 270.19M | 406.39M | 367.7M | 358.6M |
Total Liabilities | 338M | 318.07M | 383.77M | 382.82M | 403.46M |
Total Equity | 10.78M | -47.87M | 22.61M | -15.12M | -44.86M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 132.44M | 342.94M | 354.86M | 348.78M | 358.6M |
Total Liabilities | 180.76M | 168.19M | 223.35M | 338M | 403.46M |
Total Equity | -48.32M | 174.75M | 131.51M | 10.78M | -44.86M |
Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -228.82M | -76.58M | -10.6M | -69.86M | -117.35M |
Investing | 82.43M | 2.74M | 13.26M | 11.46M | 10.58M |
Financing | 129.6M | 5.66M | 63.83M | 65.28M | 71.71M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -76.52M | -93.61M | 6.69M | -228.82M | -117.35M |
Investing | -30.52M | -158.89M | 64.09M | 82.43M | 10.58M |
Financing | 86.23M | 303.42M | 1.18M | 129.6M | 71.71M |
Market Cap | 157.8M |
Price to Earnings Ratio | -1.37 |
Price to Sales Ratio | 1.23 |
Price to Cash Ratio | 1.22 |
Price to Book Ratio | -3.47 |
Dividend Yield | - |
Shares Outstanding | 151.01M |
Average Volume (1 week) | 9.8M |
Average Volume (1 Month) | 6.57M |
52 Week Change | -81.17% |
52 Week High | 6.26 |
52 Week Low | 0.54 |
Spread (Intraday) | 0.01 (0.95%) |
Company Name | Seres Therapeutics Inc |
Address |
corporation trust center wilmington, delaware 19801 |
Website | https://www.serestherapeutics.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions